AIベースの臨床試験市場：コンポーネント、機能、フェーズ、テクノロジー、アプリケーション、エンドユーザー別-世界予測2025-2030年

AIベースの臨床試験市場の2023年の市場規模は65億2,000万米ドルで、2024年には77億3,000万米ドルに達すると予測され、CAGR 18.79％で成長し、2030年には217億9,000万米ドルに達すると予測されています。

AIベースの臨床試験市場には、臨床試験プロセスを合理化し、効率性、正確性、スピードを高めるための人工知能技術の活用が含まれます。これには、患者募集、データ管理、モニタリング、予測分析への応用が含まれます。その必要性は、従来の臨床試験モデルの非効率性、高コスト、時間のかかるプロセスから生じており、医薬品開発の革新を目指す製薬企業にとってAIは魅力的な選択肢となっています。臨床試験におけるAIの最終用途は、主に製薬会社、バイオテクノロジー企業、医薬品開発業務受託機関（CRO）であり、臨床試験デザインの最適化、タイムラインの短縮、患者データに対するより深い洞察の提供による患者転帰の改善を目的としています。主な成長促進要因には、個別化医療に対する需要の高まり、ヘルスケアにおけるAIの採用拡大、より効率的な医薬品開発プロセスの必要性などがあります。AIの統合により、新薬や治療法の市場投入までの時間を大幅に短縮できるため、この分野のプレーヤーにとっては大きなチャンスとなります。しかし、データプライバシーに関する懸念、規制上のハードル、高品質なデータセットの必要性などの課題が、市場の成長を阻害する可能性があります。こうした制約を克服するため、企業は堅牢なデータ・インフラの構築、規制基準の遵守の徹底、AI新興企業やテクノロジー・プロバイダーとのパートナーシップの醸成に投資すべきです。技術革新の分野には、予測分析のための機械学習アルゴリズムの活用、データ抽出のための自然言語処理、臨床試験におけるリスクベースのモニタリングのためのAIモデルなどがあります。事業成長のためには、患者の安全性を高め、規制遵守プロセスを合理化し、リアルタイムの試験調整を促進するAI技術に注力することで、大きな利益を得ることができます。全体として、AI技術の進歩と、より効率的で費用対効果の高い臨床試験ソリューションに対する需要の高まりにより、市場は大きく成長する見通しであるが、持続的な成長には根本的な課題への対処が不可欠です。

市場力学：急速に進化するAIベースの臨床試験市場の主要市場インサイトを公開

AIベースの臨床試験市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 臨床試験の後押しと改善に役立つ人工知能のニーズ
  • ヘルスケアコストの削減ニーズの高まりとハードウェアコストの低下
  • 製薬会社の多くでAIベースの医薬品開発技術の採用が増加
• 市場抑制要因
  • 失業率の上昇につながる個人の関与の欠如
  • 欠陥診断の可能性
• 市場機会
  • AIベースの臨床試験における技術の進歩とイノベーション
  • 大手製薬企業によるAIベンダーとの合弁や提携の増加
• 市場の課題
  • EHRの相互運用性の導入に伴う懸念

ポーターのファイブフォース：AIベースの臨床試験市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、AIベースの臨床試験市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：AIベースの臨床試験市場における外部からの影響の把握

外部マクロ環境要因は、AIベースの臨床試験市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析AIベースの臨床試験市場における競合情勢の把握

AIベースの臨床試験市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスAIベースの臨床試験市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、AIベースの臨床試験市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨AIベースの臨床試験市場における成功への道筋を描く

AIベースの臨床試験市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 臨床試験の促進と改善に役立つ人工知能の必要性
    • ヘルスケア費削減のニーズの高まりとハードウェアコストの低下
    • 製薬会社のほとんどがAIベースの医薬品開発技術を採用
  • 抑制要因
    • 個人の関与の欠如が失業率の上昇につながる
    • 診断の誤りの可能性
  • 機会
    • AIベースの臨床試験における技術の進歩と革新
    • 大手製薬会社はAIベンダーとの合弁事業や提携を拡大している
  • 課題
    • EHR相互運用性の導入に伴う懸念
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 AIベースの臨床試験市場：コンポーネント別

• サービス
• ソフトウェア

第7章 AIベースの臨床試験市場：機能別

• 有害事象検出
• データ収集と分析
• 患者の募集とスクリーニング
• 予測モデリング
• 試験設計と最適化

第8章 AIベースの臨床試験市場フェーズ別

• フェーズI
• フェーズII
• フェーズIII

第9章 AIベースの臨床試験市場：技術別

• 機械学習
• 自然言語処理

第10章 AIベースの臨床試験市場：用途別

• 心血管疾患
• 感染症
• 代謝性疾患
• 神経疾患
• 腫瘍学

第11章 AIベースの臨床試験市場：エンドユーザー別

• 学術調査機関
• 契約調査機関
• 病院
• 製薬・バイオ医薬品企業

第12章 南北アメリカのAIベースの臨床試験市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第13章 アジア太平洋地域のAIベースの臨床試験市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第14章 欧州・中東・アフリカのAIベースの臨床試験市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第15章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AiCure, LLC
• Aiforia Technologies Oyj
• Antidote Technologies, Inc.
• Ardigen S.A.
• Avantor, Inc.
• BioAge Labs
• BioSymetrics Inc.
• Deep 6 AI Inc.
• Envisagenics
• Euretos Services BV
• Exscientia PLC
• GNS Healthcare
• Google LLC by Alphabet Inc.
• Innoplexus AG
• InSilico Medicine
• Intel Corporation
• International Business Machines Corporation
• Koninklijke Philips N.V.
• Median Technologies
• Nuritas Limited
• Pharmaceutical Pipeline Enhancement Strategies, LLC
• Saama Technologies, Inc.
• Symplr Software LLC
• Trials.ai, Inc. by ZS Associates, Inc.
• Unlearn.AI, Inc.

LIST OF FIGURES

• FIGURE 1. AI-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
• FIGURE 2. AI-BASED CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 21. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 26. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 27. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. AI-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. AI-BASED CLINICAL TRIALS MARKET DYNAMICS
• TABLE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ADVERSE EVENT DETECTION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA COLLECTION & ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PATIENT RECRUITMENT & SCREENING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-I, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-II, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-III, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 35. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 36. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 41. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 42. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 43. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 44. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 48. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 49. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 50. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 51. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 53. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 54. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 55. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 56. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 57. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 58. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 60. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 61. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 62. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 63. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 64. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 66. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 67. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 68. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 70. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 71. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 72. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 73. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 74. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 75. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 77. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 79. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 80. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 81. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 82. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 83. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 85. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 86. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 87. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 88. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 89. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 92. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 93. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 94. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 95. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 96. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 98. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 99. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 100. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 101. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 102. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 104. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 105. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 106. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 107. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 108. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 110. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 111. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 112. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 114. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 116. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 117. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 118. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 119. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 120. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 122. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 123. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 124. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 125. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 126. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 129. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 134. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 135. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 136. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 137. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 138. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 140. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 141. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 142. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 143. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 144. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 146. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 147. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 148. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 149. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 150. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 152. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 153. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 154. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 156. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 157. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 158. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 159. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 160. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 161. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 163. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 165. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 166. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 167. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 168. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 169. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 170. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 171. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 172. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 173. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 174. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 175. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 176. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 177. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 178. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 179. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 180. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 181. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 182. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 183. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 184. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 185. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 186. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 187. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 189. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 190. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 191. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 192. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 193. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 195. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 196. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 197. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 198. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 199. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 200. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 201. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 202. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 203. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 204. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 205. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 206. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 207. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 208. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 209. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 210. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 211. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 213. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 214. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 215. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 216. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 217. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 218. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 219. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 220. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 221. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 222. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 223. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 225. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 226. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 227. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 228. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 229. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 231. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 232. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 233. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 234. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 235. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 237. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 238. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 239. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 241. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 242. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 243. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 244. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 245. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 246. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 247. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 248. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 249. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 250. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 251. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 252. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 253. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 254. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 255. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 256. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 257. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 258. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 259. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 261. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 262. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 263. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 264. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 265. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 266. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 267. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 268. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 269. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 270. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 271. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 272. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 273. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 274. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 275. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 276. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 277. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 278. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
• TABLE 279. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
• TABLE 280. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
• TABLE 281. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 282. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 283. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 285. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

The AI-based Clinical Trials Market was valued at USD 6.52 billion in 2023, expected to reach USD 7.73 billion in 2024, and is projected to grow at a CAGR of 18.79%, to USD 21.79 billion by 2030.

The AI-based Clinical Trials market encompasses the utilization of artificial intelligence technologies to streamline the clinical trial process, enhancing efficiency, accuracy, and speed. This includes applications in patient recruitment, data management, monitoring, and predictive analytics. The necessity arises from the traditional clinical trial model's inefficiencies, high costs, and time-consuming processes, making AI an attractive alternative for pharmaceutical companies aiming to innovate drug development. AI applications in clinical trials are primarily end-used by pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) to optimize trial designs, reduce timelines, and improve patient outcomes by providing deeper insights into patient data. Key growth drivers include increasing demand for personalized medicine, the growing adoption of AI in healthcare, and the need for more efficient drug development processes. The integration of AI can significantly reduce the time to market for new drugs and therapies, presenting a major opportunity for players in this space. However, challenges such as data privacy concerns, regulatory hurdles, and the need for high-quality data sets can impede market growth. To overcome these limitations, companies should invest in building robust data infrastructures, ensuring compliance with regulatory standards, and fostering partnerships with AI startups and technology providers. Areas of innovation include leveraging machine learning algorithms for predictive analytics, natural language processing for data extraction, and AI models for risk-based monitoring in trials. For business growth, focusing on AI technologies that enhance patient safety, streamline regulatory compliance processes, and facilitate real-time trial adjustments can yield substantial benefits. Overall, the market is poised for significant growth, driven by advancements in AI technologies and increasing demand for more efficient and cost-effective clinical trial solutions, although addressing underlying challenges is crucial for sustained progress.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI-based Clinical Trials Market

The AI-based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Need for artificial Intelligence which helps in boosting and improving clinical trials
  • Rising needs to reduce healthcare costs and declining hardware costs
  • Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
• Market Restraints
  • Lack of personal involvement leading to a rise in unemployment rates
  • Possibility of a defective diagnosis
• Market Opportunities
  • Technological advancements and innovations in AI-based clinical trials
  • Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
• Market Challenges
  • Concerns associated with the adoption of EHR interoperability

Porter's Five Forces: A Strategic Tool for Navigating the AI-based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI-based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI-based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI-based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI-based Clinical Trials Market

A detailed market share analysis in the AI-based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI-based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI-based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI-based Clinical Trials Market

A strategic analysis of the AI-based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI-based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aiforia Technologies Oyj, Antidote Technologies, Inc., Ardigen S.A., Avantor, Inc., BioAge Labs, BioSymetrics Inc., Deep 6 AI Inc., Envisagenics, Euretos Services BV, Exscientia PLC, GNS Healthcare, Google LLC by Alphabet Inc., Innoplexus AG, InSilico Medicine, Intel Corporation, International Business Machines Corporation, Koninklijke Philips N.V., Median Technologies, Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Symplr Software LLC, Trials.ai, Inc. by ZS Associates, Inc., and Unlearn.AI, Inc..

Market Segmentation & Coverage

This research report categorizes the AI-based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Component, market is studied across Services and Software.
• Based on Function, market is studied across Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening, Predictive Modeling, and Trial Design & Optimization.
• Based on Phase, market is studied across Phase-I, Phase-II, and Phase-III.
• Based on Technology, market is studied across Machine Learning and Natural Language Processing.
• Based on Application, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurological Diseases, and Oncology.
• Based on End-user, market is studied across Academic & Research Institutes, Contract Research Organization, Hospitals, and Pharmaceutical & Biopharmaceutical Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Need for artificial Intelligence which helps in boosting and improving clinical trials
    • 5.1.1.2. Rising needs to reduce healthcare costs and declining hardware costs
    • 5.1.1.3. Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of personal involvement leading to a rise in unemployment rates
    • 5.1.2.2. Possibility of a defective diagnosis
  • 5.1.3. Opportunities
    • 5.1.3.1. Technological advancements and innovations in AI-based clinical trials
    • 5.1.3.2. Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
  • 5.1.4. Challenges
    • 5.1.4.1. Concerns associated with the adoption of EHR interoperability
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. AI-based Clinical Trials Market, by Component

• 6.1. Introduction
• 6.2. Services
• 6.3. Software

7. AI-based Clinical Trials Market, by Function

• 7.1. Introduction
• 7.2. Adverse Event Detection
• 7.3. Data Collection & Analysis
• 7.4. Patient Recruitment & Screening
• 7.5. Predictive Modeling
• 7.6. Trial Design & Optimization

8. AI-based Clinical Trials Market, by Phase

• 8.1. Introduction
• 8.2. Phase-I
• 8.3. Phase-II
• 8.4. Phase-III

9. AI-based Clinical Trials Market, by Technology

• 9.1. Introduction
• 9.2. Machine Learning
• 9.3. Natural Language Processing

10. AI-based Clinical Trials Market, by Application

• 10.1. Introduction
• 10.2. Cardiovascular Diseases
• 10.3. Infectious Diseases
• 10.4. Metabolic Diseases
• 10.5. Neurological Diseases
• 10.6. Oncology

11. AI-based Clinical Trials Market, by End-user

• 11.1. Introduction
• 11.2. Academic & Research Institutes
• 11.3. Contract Research Organization
• 11.4. Hospitals
• 11.5. Pharmaceutical & Biopharmaceutical Companies

12. Americas AI-based Clinical Trials Market

• 12.1. Introduction
• 12.2. Argentina
• 12.3. Brazil
• 12.4. Canada
• 12.5. Mexico
• 12.6. United States

13. Asia-Pacific AI-based Clinical Trials Market

• 13.1. Introduction
• 13.2. Australia
• 13.3. China
• 13.4. India
• 13.5. Indonesia
• 13.6. Japan
• 13.7. Malaysia
• 13.8. Philippines
• 13.9. Singapore
• 13.10. South Korea
• 13.11. Taiwan
• 13.12. Thailand
• 13.13. Vietnam

14. Europe, Middle East & Africa AI-based Clinical Trials Market

• 14.1. Introduction
• 14.2. Denmark
• 14.3. Egypt
• 14.4. Finland
• 14.5. France
• 14.6. Germany
• 14.7. Israel
• 14.8. Italy
• 14.9. Netherlands
• 14.10. Nigeria
• 14.11. Norway
• 14.12. Poland
• 14.13. Qatar
• 14.14. Russia
• 14.15. Saudi Arabia
• 14.16. South Africa
• 14.17. Spain
• 14.18. Sweden
• 14.19. Switzerland
• 14.20. Turkey
• 14.21. United Arab Emirates
• 14.22. United Kingdom

15. Competitive Landscape

• 15.1. Market Share Analysis, 2023
• 15.2. FPNV Positioning Matrix, 2023
• 15.3. Competitive Scenario Analysis
• 15.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AiCure, LLC
• 2. Aiforia Technologies Oyj
• 3. Antidote Technologies, Inc.
• 4. Ardigen S.A.
• 5. Avantor, Inc.
• 6. BioAge Labs
• 7. BioSymetrics Inc.
• 8. Deep 6 AI Inc.
• 9. Envisagenics
• 10. Euretos Services BV
• 11. Exscientia PLC
• 12. GNS Healthcare
• 13. Google LLC by Alphabet Inc.
• 14. Innoplexus AG
• 15. InSilico Medicine
• 16. Intel Corporation
• 17. International Business Machines Corporation
• 18. Koninklijke Philips N.V.
• 19. Median Technologies
• 20. Nuritas Limited
• 21. Pharmaceutical Pipeline Enhancement Strategies, LLC
• 22. Saama Technologies, Inc.
• 23. Symplr Software LLC
• 24. Trials.ai, Inc. by ZS Associates, Inc.
• 25. Unlearn.AI, Inc.